Impact of vitamin K dosing during sorafenib treatment for hepatocellular carcinoma: Effect on ischemic tumor cell damage caused by sorafenib.

被引：0
|
作者：
Haruna, Yoshimichi
Hasegawa, Noriko
Imanaka, Kazuho
Inoue, Atsuo
Kudo, Masatoshi
机构：
[1] Osaka Gen Med Ctr, Osaka, Japan
[2] Kinki Univ, Sch Med, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15585
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15585
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effect of an lncRNA-associated ceRNA regulatory network in MVI-positive hepatocellular carcinoma on their sensitivity to sorafenib.
    Luo, Zhiwen
    Bi, Xinyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma
    A Lamarca
    J Feliu
    J Barriuso
    British Journal of Cancer, 2012, 106 : 1246 - 1246
  • [33] Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells
    Wu, Man
    Zhao, Guanren
    Zhuang, Xiaomei
    Zhang, Tianhong
    Zhang, Ce
    Zhang, Wenpeng
    Zhang, Zhenqing
    ONCOTARGETS AND THERAPY, 2018, 11 : 2945 - 2954
  • [34] VITAMIN K DOSING AND BRANCHED CHAIN AMINO ACIDS SUPPLEMENTATION COULD IMPROVE THE PROGNOSIS OF SORAFENIB-TREATED PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Haruna, Y.
    Inoue, A.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S398 - S399
  • [35] ASSESSMENT OF TUMOR PERFUSION BY PERFUSION CT IS ABLE TO REGISTER TREATMENT EFFICACY AND PREDICT TUMOR PROGRESSION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB. DIFFERENCES BETWEEN RESPONDING AND NON RESPONDING PATIENTS UNDERGOING SORAFENIB THERAPY
    Elisa Reig, Maria
    Rimola, Jordi
    Forner, Alejandro
    Rodriguez de Lope, Carlos
    Ayuso, Carmen
    Llovet, Josep M.
    Bruix, Jordi
    HEPATOLOGY, 2009, 50 (04) : 1091A - 1091A
  • [36] Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
    Zhang, Yafei
    Zhang, Bicheng
    Zhang, Anran
    Zhao, Yong
    Zhao, Jie
    Liu, Jian
    Gao, Jianfei
    Fang, Dianchun
    Rao, Zhiguo
    CLINICS, 2012, 67 (09) : 1093 - 1099
  • [37] GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE
    Mathurin, P.
    Castells, L.
    Bodoky, G.
    Stal, P.
    Bronowicki, J. -P.
    Gerolami, R.
    Daniele, B.
    Vazquez, J. T.
    Serejo, F.
    Croitoru, A.
    Hubert, A.
    Gorbunova, V.
    Ratziu, V.
    Papandreou, C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S399 - S400
  • [38] Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma
    Eng, F. C. S.
    Easson, A. M.
    Szentgyorgyi, E.
    Knox, J. J.
    EJSO, 2009, 35 (02): : 219 - 221
  • [39] Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma
    Lucas, Elodie
    Aubourg, Alexandre
    Bacq, Yannick
    Perarnau, Jean-Marc
    DIGESTIVE AND LIVER DISEASE, 2011, 43 (11) : 920 - 920
  • [40] Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus
    Zhang, Yong-Fa
    Wei, Wei
    Wang, Jia-Hong
    Xu, Li
    Jian, Pei-En
    Xiao, Cheng-Zuo
    Zhong, Xiao-Ping
    Shi, Ming
    Guo, Rong-Ping
    ONCOTARGETS AND THERAPY, 2016, 9 : 4239 - 4246
12345